Investor FAQs

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

To learn more about Ionis, visit www.ionis.com and follow us on X (Twitter) and LinkedIn.
 

Ionis Pharmaceuticals, Inc. was founded in 1989. Ionis conducted its initial public offering two years later in 1991.

Ionis is traded on the NASDAQ stock exchange under the symbol IONS. Please note that prior to December 22, 2015 our symbol was ISIS and prior to February 21, 2002 our symbol was ISIP.

To view a PDF file of the annual reports from 2020-2023 click here. If you would like to receive a hard copy of any of Ionis' annual reports, please click here. Please note that if you are requesting that we send the annual report to an address outside of the U.S. (including Canada and Mexico) you must include your telephone number. The US Postal Service requires a phone number for shipments out of the U.S.

Contact our Transfer Agent, Equiniti Trust Company, LLC 
48 Wall Street, Floor 23                              
New York, NY 10005       
Tel 1-800-937-5449
Tel 1-718-921-8124
helpAST@equiniti.com